Terbutalin etkileşimleri

beta adrenerjik agonist sınıfından Terbutalin (Brethine) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 206 belgelenmiş etkileşim var: 60 majör, 125 orta, 19 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 2 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (60)

  • AdrenalinsempatomimetikMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • AmfetaminMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Amfetamin ve dekstroamfetaminMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Arformoterolbeta adrenerjik agonistMajör

    Drug Interactions The concomitant use of terbutaline sulfate tablets with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. (Terbutalin etiketi, İlaç etkileşimleri)

  • ArmodafinilMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Artikain ve adrenalinlokal anestezikMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • AtazanavirantiretroviralMajör

    Inhaled beta agonist: salmeterol ↑ salmeterol Coadministration of salmeterol with REYATAZ is not recommended. (Atazanavir etiketi, İlaç etkileşimleri)

  • BenzfetaminMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Budesonid ve formoterolkortikosteroidMajör

    Drug Interactions The concomitant use of terbutaline sulfate tablets with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. (Terbutalin etiketi, İlaç etkileşimleri)

  • Bupivakain ve adrenalinlokal anestezikMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • DarunavirantiretroviralMajör

    Inhaled beta agonist : salmeterol ↑ salmeterol Co-administration of salmeterol and PREZISTA/ritonavir is not recommended. (Darunavir etiketi, İlaç etkileşimleri)

  • Darunavir ve kobisistatantiretroviralMajör

    Inhaled beta agonist: salmeterol ↑ salmeterol Co-administration with salmeterol is not recommended and may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia. (Darunavir ve kobisistat etiketi, İlaç etkileşimleri)

  • DeksmetilfenidatMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • DekstroamfetaminMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • DietilpropionMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • DobutaminsempatomimetikMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • DroksidopasempatomimetikMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • DronabinolkannabinoidMajör

    Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (Dronabinol etiketi, Uyarılar ve önlemler)

  • EfedrinsempatomimetikMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Inhaled Beta Agonist: salmeterol ↑ salmeterol Coadministration of salmeterol and GENVOYA is not recommended. (Elvitegravir, kobisistat, emtrisitabin ve tenofovir etiketi, İlaç etkileşimleri)

  • Ergotamin ve kafeinergot alkaloidiMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • FendimetrazinMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • FenelzinMAO inhibitörüMajör

    The potentiation of sympathomimetic substances and related compounds by MAO inhibitors may result in hypertensive crises (see WARNINGS ). (Fenelzin etiketi, Kontrendikasyonlar)

  • FenilefrindekonjestanMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • FenterminMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Fentermin ve topiramatMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Flutikazon ve salmeterolkortikosteroidMajör

    Drug Interactions The concomitant use of terbutaline sulfate tablets with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. (Terbutalin etiketi, İlaç etkileşimleri)

  • Formoterolbeta adrenerjik agonistMajör

    Drug Interactions The concomitant use of terbutaline sulfate tablets with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. (Terbutalin etiketi, İlaç etkileşimleri)

  • FosamprenavirantiretroviralMajör

    Inhaled beta-agonist: Salmeterol ↑ Salmeterol Concurrent administration of salmeterol with fosamprenavir calcium is not recommended. (Fosamprenavir etiketi, İlaç etkileşimleri)

  • İmipramintrisiklik antidepresanMajör

    Avoid the use of preparations, such as decongestants and local anesthetics, that contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines. (İmipramin etiketi, İlaç etkileşimleri)

  • İpratropium ve salbutamolantikolinerjikMajör

    Drug Interactions The concomitant use of terbutaline sulfate tablets with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. (Terbutalin etiketi, İlaç etkileşimleri)

  • İzoprenalinbeta adrenerjik agonistMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Kokainlokal anestezikMajör

    Known Hypersensitivity or Idiosyncrasy to the Sympathomimetic Amines NUMBRINO is contraindicated in patients with a known history of hypersensitivity to cocaine or to the components of the nasal solution. (Kokain etiketi, Uyarılar ve önlemler)

  • Levosalbutamolbeta adrenerjik agonistMajör

    Drug Interactions The concomitant use of terbutaline sulfate tablets with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. (Terbutalin etiketi, İlaç etkileşimleri)

  • Levotiroksin ve liyotironintiroid hormonuMajör

    Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Levotiroksin ve liyotironin etiketi, Kutulu uyarı)

  • Lidokain ve adrenalinlokal anestezikMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • LisdeksamfetaminMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Liyotironintiroid hormonuMajör

    • Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (Liyotironin etiketi, Kutulu uyarı)

  • MetamfetaminMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • MetilfenidatMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Midodrinalfa adrenerjik agonistMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Mirabegronbeta adrenerjik agonistMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • ModafinilMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • OksimetazolindekonjestanMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Orfenadrin, aspirin ve kafeinkas gevşeticiMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • Prilokain ve adrenalinlokal anestezikMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • PsödoefedrindekonjestanMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • RibavirinantiviralMajör

    IF INITIATION OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP TREATMENT APPEARS TO PRODUCE SUDDEN DETERIORATION OF RESPIRATORY FUNCTION, TREATMENT SHOULD BE STOPPED AND REINSTITUTED ONLY WITH EXTREME CAUTION, CONTINUOUS MONITORING AND CONSIDERATION OF CONCOMITANT ADMINISTRATION OF BRONCHODILATORS (SEE WARNINGS ). (Ribavirin etiketi, Kutulu uyarı)

  • RoflumilastPDE4 inhibitörüMajör

    Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (Roflumilast etiketi, Uyarılar ve önlemler)

  • Salbutamolbeta adrenerjik agonistMajör

    Drug Interactions The concomitant use of terbutaline sulfate tablets with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. (Terbutalin etiketi, İlaç etkileşimleri)

  • Salmeterolbeta adrenerjik agonistMajör

    Drug Interactions The concomitant use of terbutaline sulfate tablets with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. (Terbutalin etiketi, İlaç etkileşimleri)

  • SolriamfetolMSS uyarıcısıMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

  • TranilsiprominMAO inhibitörüMajör

    …(SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) tricyclic antidepressants other antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as pseudoephedrine, phenylephrine and ephedrine. (Tranilsipromin etiketi, Kutulu uyarı)

  • Umeklidinyum ve vilanterolantikolinerjikMajör

    Drug Interactions The concomitant use of terbutaline sulfate tablets with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. (Terbutalin etiketi, İlaç etkileşimleri)

  • Vibegronbeta adrenerjik agonistMajör

    Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Terbutalin etiketi, Kontrendikasyonlar)

Orta düzey etkileşimler (125)

  • AklidinyumantikolinerjikOrta

    Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (Aklidinyum etiketi, İlaç etkileşimleri)

  • Alogliptin ve metforminDPP-4 inhibitörüOrta

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (Alogliptin ve metformin etiketi, İlaç etkileşimleri)

  • Amiloridpotasyum tutucu diüretikOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Amitriptilintrisiklik antidepresanOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Amoksapintrisiklik antidepresanOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Asebutololbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • Asetazolamidkarbonik anhidraz inhibitörüOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Atenololbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • Atomoksetinnoradrenalin geri alım inhibitörüOrta

    Albuterol (or other beta 2 agonists): Increase the frequency of monitoring blood pressure and heart rate. (Atomoksetin etiketi, İlaç etkileşimleri)

  • Azelastin ve flutikazonantihistaminikOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • AztreonamantibiyotikOrta

    Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (Aztreonam etiketi, Uyarılar ve önlemler)

  • BeklometazonkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Betaksololbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • BetametazonkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • Bisoprololbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Brimonidin ve timololalfa adrenerjik agonistOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • BudesonidkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • Bumetanidkıvrım (loop) diüretiğiOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • BupropionantidepresanOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • DeflazakortkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • DeksametazonkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • Desipramintrisiklik antidepresanOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • DesonidkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Digoksindijital glikozidiOrta

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (Digoksin etiketi, İlaç etkileşimleri)

  • DisikloverinantikolinerjikOrta

    …drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (Disikloverin etiketi, İlaç etkileşimleri)

  • Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (Doksapram etiketi, İlaç etkileşimleri)

  • Doksepintrisiklik antidepresanOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Dorzolamid ve timololkarbonik anhidraz inhibitörüOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • DuloksetinSNRIOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Enalapril ve hidroklorotiyazidACE inhibitörüOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Eplerenonaldosteron antagonistiOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Esmololbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • EssitalopramSSRIOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Etakrinik asitkıvrım (loop) diüretiğiOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • FludrokortizonkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • FlunisolidkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • FluoksetinSSRIOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • FluosinonidkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • FlutikazonkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • FluvoksaminSSRIOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Furosemidkıvrım (loop) diüretiğiOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • GlimepiridsülfonilüreOrta

    …somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (Glimepirid etiketi, İlaç etkileşimleri)

  • GlipizidsülfonilüreOrta

    …olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. (Glipizid etiketi, İlaç etkileşimleri)

  • HalobetazolkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • Hidroklorotiyazidtiyazid diüretikOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • HidrokortizonkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • İndapamidtiyazid diüretikOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • İnsülin aspartinsülinOrta

    …Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (İnsülin aspart etiketi, İlaç etkileşimleri)

  • İnsülin degludekinsülinOrta

    …Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (İnsülin degludek etiketi, İlaç etkileşimleri)

  • İnsülin detemirinsülinOrta

    …Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (İnsülin detemir etiketi, İlaç etkileşimleri)

  • İnsülin glarjininsülinOrta

    …Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (İnsülin glarjin etiketi, İlaç etkileşimleri)

  • İnsülin lisproinsülinOrta

    …Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (İnsülin lispro etiketi, İlaç etkileşimleri)

  • İrbesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • İzoniazidantibiyotikOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Kandesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Karvedilolbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • KetaminMSS depresanıOrta

    Sympathomimetics and Vasopressin : Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine [see Drug Interactions ( 7.2 )] . (Ketamin etiketi, Uyarılar ve önlemler)

  • Kinapril ve hidroklorotiyazidACE inhibitörüOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • KlobetazolkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • Klomipramintrisiklik antidepresanOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Klorotiyazidtiyazid diüretikOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Klortalidontiyazid diüretikOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Labetalolbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Levotiroksintiroid hormonuOrta

    Sympathomimetics Concurrent use may of sympathomimetics and levothyroxine may increase the effects of sympathomimetics or thyroid hormone. (Levotiroksin etiketi, İlaç etkileşimleri)

  • LinezolidantibiyotikOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Losartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Interrupt MARGENZA infusion in patients experiencing dyspnea or clinically significant hypotension and intervene with medical therapy which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators and oxygen. (Margetuksimab etiketi, Uyarılar ve önlemler)

  • Metilen mavisiMAO inhibitörüOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • MetilprednizolonkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • Metolazontiyazid diüretikOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Metoprololbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • MirtazapinantidepresanOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • MometazonkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • Nadololbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • Naltrekson ve bupropionopioid antagonistiOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • NateglinidmeglitinidOrta

    Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (Nateglinid etiketi, İlaç etkileşimleri)

  • Nebivololbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • NefazodonantidepresanOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Nortriptilintrisiklik antidepresanOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Olanzapin ve fluoksetinantipsikotikOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Olmesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Olmesartan, amlodipin ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Olopatadin ve mometazonantihistaminikOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • ParoksetinSSRIOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Pindololbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • Pioglitazon ve glimepiridtiyazolidindionOrta

    …somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (Pioglitazon ve glimepirid etiketi, İlaç etkileşimleri)

  • PrednizolonkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • PrednizonkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • Propranololbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • Protriptilintrisiklik antidepresanOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • RasajilinMAO inhibitörüOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • RitonavirantiretroviralOrta

    Bronchodilator: theophylline ↓ theophylline Increased dosage of theophylline may be required; therapeutic monitoring should be considered. (Ritonavir etiketi, İlaç etkileşimleri)

  • SelejilinMAO inhibitörüOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • SertralinSSRIOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • SiklesonidkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • SitalopramSSRIOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Sotalolbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • Spironolaktonaldosteron antagonistiOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Spironolakton ve hidroklorotiyazidaldosteron antagonistiOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Süksinilkolinnöromüsküler blokerOrta

    …the Neuromuscular Blocking Action of Succinylcholine : promazine, oxytocin, aprotinin, certain non-penicillin antibiotics, quinidine, β-adrenergic blockers, procainamide, lidocaine, trimethaphan, lithium carbonate, magnesium salts, quinine, chloroquine, isoflurane, desflurane, metoclopramide, terbutaline, and drugs that reduce plasma cholinesterase activity. (Süksinilkolin etiketi, İlaç etkileşimleri)

  • Telmisartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Timololbeta blokerOrta

    In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

  • TiotropiumantikolinerjikOrta

    Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (Tiotropium etiketi, İlaç etkileşimleri)

  • Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (Tolkapon etiketi, İlaç etkileşimleri)

  • Torasemidkıvrım (loop) diüretiğiOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (Trastuzumab etiketi, Uyarılar ve önlemler)

  • TrazodonantidepresanOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • TriamsinolonkortikosteroidOrta

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (Terbutalin etiketi, Uyarılar)

  • Triamterenpotasyum tutucu diüretikOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Triamteren ve hidroklorotiyazidpotasyum tutucu diüretikOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • Trimipramintrisiklik antidepresanOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • Valsartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • VenlafaksinSNRIOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • VilazodonSSRIOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • VortioksetinantidepresanOrta

    Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Terbutalin etiketi, Önlemler)

  • ZanamivirantiviralOrta

    If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (Zanamivir etiketi, Uyarılar ve önlemler)

Minör değinmeler (19)

  • AkarbozantidiyabetikMinör

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (Akarboz etiketi, İlaç etkileşimleri)

  • Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (Bevasizumab etiketi, Uyarılar ve önlemler)

  • Bromokriptindopamin agonistiMinör

    There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (Bromokriptin etiketi, İlaç etkileşimleri)

  • Dapagliflozin ve metforminSGLT2 inhibitörüMinör

    These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Dapagliflozin ve metformin etiketi, İlaç etkileşimleri)

  • Empagliflozin ve metforminSGLT2 inhibitörüMinör

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Empagliflozin ve metformin etiketi, İlaç etkileşimleri)

  • GlibenklamidsülfonilüreMinör

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Glibenklamid etiketi, İlaç etkileşimleri)

  • Glibenklamid ve metforminsülfonilüreMinör

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Glibenklamid ve metformin etiketi, İlaç etkileşimleri)

  • Glipizid ve metforminsülfonilüreMinör

    These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Glipizid ve metformin etiketi, Önlemler)

  • İpratropiumantikolinerjikMinör

    Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (İpratropium etiketi, Uyarılar ve önlemler)

  • Linagliptin ve metforminDPP-4 inhibitörüMinör

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Linagliptin ve metformin etiketi, İlaç etkileşimleri)

  • MetforminbiguanidMinör

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Metformin etiketi, İlaç etkileşimleri)

  • Pioglitazon ve metformintiyazolidindionMinör

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Pioglitazon ve metformin etiketi, İlaç etkileşimleri)

  • In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported in 29% (5/17) and 0% (0/13) of patients with and without a diagnosis of asthma, respectively. (Regüler insülin (insan) etiketi, Uyarılar ve önlemler)

  • RepaglinidmeglitinidMinör

    …antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Repaglinid etiketi, İlaç etkileşimleri)

  • RituksimabimmünosüpresanMinör

    Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (Rituksimab etiketi, Uyarılar ve önlemler)

  • Saksagliptin ve metforminDPP-4 inhibitörüMinör

    These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Saksagliptin ve metformin etiketi, İlaç etkileşimleri)

  • Sitagliptin ve metforminDPP-4 inhibitörüMinör

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Sitagliptin ve metformin etiketi, İlaç etkileşimleri)

  • TobramisinaminoglikozidMinör

    In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (Tobramisin etiketi, İlaç etkileşimleri)

  • UmeklidinyumantikolinerjikMinör

    Acute symptoms should be treated with an inhaled, short-acting beta 2 -agonist. (Umeklidinyum etiketi, Uyarılar ve önlemler)

Anlamlı etkileşim olmadığı bildirilenler (2)

  • AminofilinmetilksantinEtkileşim yok

    …nizatidine norfloxacin ofloxacin omeprazole prednisone, prednisolone ranitidine rifabutin roxithromycin sorbitol (purgative doses do not inhibit theophylline absorption) sucralfate terbutaline, systemic terfenadine tetracycline tocainide The Effect of Other Drugs on Theophylline Serum Concentration Measurements: Most serum theophylline assays in clinical use are… (Aminofilin etiketi, İlaç etkileşimleri)

  • TeofilinmetilksantinEtkileşim yok

    …ranitidine famotidine rifabutin felodipine roxithromycin finasteride Sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin * Refer to PRECAUTIONS , Drug Interactions for information regarding… (Teofilin etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Terbutalin ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.